Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $165 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Cargojet Inc. (CJT:CN) (CGGJF) PT Raised to $128 at TD Cowen, maintains bullish call
• Empress Royalty acquires Tongon gold stream for $62M